Gains full-rights to Cormorant’s HuMax-IL8 antibody program and lead asset HuMax-IL8 in Phase 1/2 Development
Broadens Bristol-Myers Squibb’s oncology pipeline focus on the tumor microenvironment and combination therapy
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals | BMS Newsroom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.